login
login
Image header Agence Europe

Europe Daily Bulletin No. 12695

Contents Publication in full By article 1 / 26
EU RESPONSE TO COVID-19
HEALTH: Johnson & Johnson vaccine’s turn to come under scrutiny at European Medicines Agency for blood clots

The European Medicines Agency (EMA) announced, on Friday 9 April, that an investigation had been opened by its safety committee (PRAC) to assess the risks of thromboembolic events linked to the Covid-19 vaccine produced by the pharmaceutical company Janssen Pharmaceutica NV, a Belgian subsidiary of the US group Johnson & Johnson.

The PRAC “has started a review of a safety signal”: in other words, the reports it has received about these thromboembolic events (blood clots, leading to the...

Contents

EU RESPONSE TO COVID-19
EXTERNAL ACTION
SECTORAL POLICIES
FUNDAMENTAL RIGHTS - SOCIETAL ISSUES
COUNCIL OF EUROPE
ECONOMY - FINANCE - BUSINESS
NEWS BRIEFS
CALENDAR
CALENDAR EXTRA